FDA Recall Signals: Moringa Salmonella Risk in Context
In August 2026, the FDA's enforcement reporting system logged a Class I recall for Zen Principle Naturals Moringa Leaf Powder capsules, a 900mg product sold in 180-count bottles and manufactured for a company based in Incline Village, Nevada. The stated reason was possible Salmonella contamination, and the recalling firm was listed as Factory6, Inc. Distribution was described as limited to Nevada for further distribution, and the case was marked ongoing at the time of publication [SRC: FDA-H-1222-2026]. Taken alone, that entry might read as a signal about moringa as an ingredient. Placed next to a dozen other 2026 enforcement reports, a different picture emerges — one about the mechanics of supplement manufacturing and labeling oversight rather than about any single botanical.
This brief walks through what the Zen Principle Naturals record actually says, how FDA recall classifications work, what a second moringa-linked recall earlier in the year adds to the picture, and where the broader 2026 enforcement data does and does not support broader conclusions about supplement safety.
What the record says — and doesn't say
FDA enforcement reports are retrospective entries in the Recall Enterprise System, not real-time alerts and not adjudicated findings of harm. The Zen Principle Naturals entry describes a "possible" contamination — language that reflects a triggering test result or supplier notification rather than a confirmed illness outbreak tied to this specific lot [SRC: FDA-H-1222-2026]. The report does not state that any consumer became sick, and it does not identify a root cause such as a specific supplier, growing region, or processing step. The distribution footprint recorded is narrow: product moved to Nevada for further distribution, which is a smaller scope than several other entries in the same reporting period [SRC: FDA-H-1222-2026].
That narrowness matters for interpretation. A Class I classification describes the severity of a reasonably possible health consequence if the hazard is real and consumed — not the number of units affected, not the number of states involved, and not confirmation that the hazard materialized in every unit distributed. Severity classification and distribution scope are two separate axes, and conflating them is one of the most common misreadings of recall data.
How FDA classifies recalls
The FDA sorts recalls into three classes based on the reasonably foreseeable health consequences of the issue, not on how many products were shipped or how many complaints were received. Class I is reserved for situations where there is a reasonable probability that use of the product will cause serious adverse health consequences or death. Class II covers situations where use may cause temporary or medically reversible harm, or where the probability of serious harm is remote. Class III applies to violations unlikely to cause any adverse health consequence.
In this packet, the classification split illustrates that range clearly. Alongside the Zen Principle Naturals moringa entry, Class I designations were also applied to a nootropic-marketed product found to contain unapproved stimulant and research-chemical ingredients including tianeptine, 1,4-DMAA, and aniracetam [SRC: FDA-H-1178-2026]; to two separate mitragynine-related chewable tablet products where lab analysis found the active ingredient present at levels exceeding the labeled specification [SRC: FDA-H-1108-2026] [SRC: FDA-H-1107-2026]; to a tejocote root supplement found to contain yellow oleander, a plant toxin unrelated to the labeled ingredient [SRC: FDA-H-0647-2026]; and to a second, earlier moringa-containing product — a "Super Greens" blend — recalled for possible Salmonella Typhimurium contamination [SRC: FDA-H-0433-2026]. A separate moringa capsule product from a different company was also recalled in March 2026 under a Class I Salmonella designation, with nationwide and extensive international distribution, before that recall was later marked terminated [SRC: FDA-H-0546-2026].
By contrast, Class II designations in the same window covered a mix of labeling omissions and quality defects: undisclosed fish-derived marine collagen on a skin-supplement label [SRC: FDA-H-1190-2026], undeclared Yellow #5 dye in two related eye-health and general supplement products from the same manufacturer [SRC: FDA-H-1135-2026] [SRC: FDA-H-1134-2026], premature lipid oxidation causing off-odor and taste defects in a gut-health powder [SRC: FDA-H-1109-2026], black particulate foreign matter in a liquid vitamin B-complex product [SRC: FDA-H-0809-2026], and undeclared milk allergen on two separate colostrum-containing products [SRC: FDA-H-0483-2026] [SRC: FDA-H-0537-2026]. None of these Class II reasons involve pathogenic contamination; they reflect labeling accuracy and product-quality lapses that the agency judged less likely to cause serious harm.
Reading the moringa recalls side by side
Two moringa-containing products appear in this packet with Class I Salmonella-related reasons: the Zen Principle Naturals moringa leaf powder capsules [SRC: FDA-H-1222-2026] and the Rosabella-branded moringa capsules distributed by Ambrosia Brands [SRC: FDA-H-0546-2026]. A third product, a multi-ingredient "Super Greens" powder that included moringa among nine other plant ingredients, was recalled for Salmonella Typhimurium contamination as well [SRC: FDA-H-0433-2026]. Three recalls touching moringa-containing products within roughly a seven-month reporting window is a pattern worth noting, but the packet does not establish a common cause across them. The recalling firms are different — Factory6, Ambrosia Brands, and Superfoods, Inc. — and the products differ in formulation, with only one being a single-ingredient moringa capsule matching the anchor record precisely. The distribution scope also varies enormously: the Ambrosia Brands recall reached nationwide U.S. territories and dozens of countries internationally [SRC: FDA-H-0546-2026], while the Zen Principle Naturals recall was confined to Nevada [SRC: FDA-H-1222-2026], and the Superfoods recall reached nationwide U.S. distribution plus the United Kingdom [SRC: FDA-H-0433-2026]. None of the three records in this packet identifies a shared supplier, farm, or processing facility. Salmonella is a contamination risk associated with agricultural handling, drying, and processing conditions broadly across many raw plant-derived powders — not a hazard mechanistically specific to moringa as a botanical. Nothing in these records supports a conclusion that moringa itself carries elevated intrinsic risk relative to other leaf-powder or green-blend ingredients; the recurring theme is more plausibly tied to supply-chain and manufacturing controls for raw powdered botanicals generally.
What this does not mean
This pattern of enforcement reports does not mean moringa is uniquely or inherently unsafe as a dietary ingredient. It does not mean every moringa product on the market carries contamination risk, and it does not mean the three recalled products shared a common source, supplier, or manufacturing defect — the packet contains no evidence linking them beyond the shared ingredient and the shared hazard category. It also does not mean the Zen Principle Naturals recall has been resolved: the record status is listed as ongoing, and enforcement report status can change as an investigation proceeds [SRC: FDA-H-1222-2026].
More broadly, this dataset should not be read as a comprehensive survey of supplement industry safety. It is a sample of enforcement actions that reached the public reporting system in one calendar year, filtered through whatever combination of firm self-reporting, FDA inspection activity, and consumer or retailer complaints triggered each action. It says nothing about the much larger number of supplement products that were never flagged, and it cannot be used to estimate contamination rates, prevalence, or risk levels across the supplement category as a whole. A recall record confirms that an issue was identified and reported; it does not confirm how many units were affected, whether any consumer was harmed, or whether the underlying hazard was present in the full production run.
Limits of the evidence
Several boundaries apply to this brief and to the underlying source packet. First, these are enforcement records, not epidemiological studies — they document regulatory and firm actions, not confirmed illness counts or dose-response data. Second, "possible" contamination language in several entries, including the anchor record, indicates a triggering finding rather than a fully confirmed and quantified hazard in every distributed unit [SRC: FDA-H-1222-2026]. Third, recall status fields (ongoing, terminated, completed) are dynamic administrative markers that can change after publication; a status captured at one point in time should not be treated as final [SRC: FDA-H-0546-2026] [SRC: FDA-H-0483-2026]. Fourth, this packet cannot support any comparison between moringa and other ingredient categories in terms of relative contamination risk, since no denominator — such as total moringa products on the market — is available. Finally, none of these records constitutes a real-time consumer alert; readers concerned about a specific product should consult the FDA's current enforcement report listings directly rather than relying on a historical summary.
Selected sources
- FDA Recalls, Market Withdrawals, & Safety Alerts — Enforcement Reports [SRC: FDA-H-1222-2026]
- FDA Enforcement Report H-0546-2026 (Rosabella Moringa) [SRC: FDA-H-0546-2026]
- FDA Enforcement Report H-0433-2026 (Live It Up Super Greens) [SRC: FDA-H-0433-2026]
Editorial note
This brief was prepared from publicly available FDA enforcement report summaries current as of their listed publication dates in 2026. Enforcement records are updated by the agency over time; status designations such as "ongoing," "terminated," or "completed" reflect a snapshot and may not represent the current state of any given case. This article draws conclusions only from the records supplied and does not incorporate independent laboratory data, epidemiological surveillance, or firm statements beyond what appears in the cited reports.
This article is for educational purposes only and has not been evaluated by the Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for consulting the FDA's current recall listings or a qualified healthcare provider regarding any specific product concern.
